Lyn Baranowski
Lyn Baranowski is the Chief Executive Officer of Avalyn Pharma, a clinical-stage biopharmaceutical company focused on developing targeted medicines for patients with rare lung diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication directly to the site of disease.
Lyn has more than two decades of experience leading a vast array of functions in biotech, big pharma, and venture capital firms with a focus in the immunology and respiratory therapeutic areas. Prior to joining Avalyn, Ms. Baranowski served as Chief Operating Officer at Altavant Sciences, a biopharmaceutical company that successfully built and developed a portfolio of therapies for rare respiratory diseases prior to its 2019 acquisition by Sumitomo Dainippon. Earlier in her career, she served in senior-level corporate development and commercial roles, including Vice President of Commercial Development at Pearl Therapeutics, which successfully developed a portfolio of asthma and chronic obstructive pulmonary disease (COPD) medicines prior to its sale to AstraZeneca for $1.15B in 2013; and Vice President at a healthcare-focused venture capital firm based in New York. She previously held roles in business development, marketing and public affairs with Novartis Pharmaceuticals in Switzerland and the U.S.
She earned an MBA from Harvard Business School and a Bachelor of Arts from American University. In addition to her role at Avalyn, Ms. Baranowski serves on the Board of Advisors for Life Science Cares and the planning committee for the American Thoracic Society’s Respiratory Innovation Summit, an annual meeting that unites the innovators, investors, and clinicians who are leading the fight to create powerful new treatments for deadly and crippling diseases of the lungs and airways. She was recognized as the 2024 PharmaVoice 100 recipient for her commitment to innovation, respiratory medicine, and patients.